Werewolf Therapeutics Future Growth
Future criteria checks 2/6
Werewolf Therapeutics's earnings are forecast to decline at 17% per annum while its annual revenue is expected to grow at 31% per year. EPS is expected to decline by 6.3% per annum.
Key information
-17.0%
Earnings growth rate
-6.3%
EPS growth rate
| Biotechs earnings growth | 24.7% |
| Revenue growth rate | 31.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 03 Jun 2024 |
Recent future growth updates
Recent updates
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 13 | -87 | -53 | N/A | 4 |
| 12/31/2025 | 12 | -69 | -46 | N/A | 5 |
| 12/31/2024 | 3 | -68 | -63 | N/A | 5 |
| 3/31/2024 | 16 | -42 | -39 | -38 | N/A |
| 12/31/2023 | 20 | -37 | -33 | -33 | N/A |
| 9/30/2023 | 26 | -37 | -41 | -40 | N/A |
| 6/30/2023 | 25 | -41 | -50 | -47 | N/A |
| 3/31/2023 | 21 | -50 | -40 | -37 | N/A |
| 12/31/2022 | 16 | -54 | -44 | -41 | N/A |
| 9/30/2022 | 9 | -60 | -45 | -41 | N/A |
| 6/30/2022 | 4 | -62 | -41 | -39 | N/A |
| 3/31/2022 | N/A | -115 | -50 | -50 | N/A |
| 12/31/2021 | N/A | -202 | -43 | -43 | N/A |
| 9/30/2021 | N/A | -205 | -36 | -36 | N/A |
| 6/30/2021 | N/A | -197 | -29 | -29 | N/A |
| 3/31/2021 | N/A | -127 | -23 | -23 | N/A |
| 12/31/2020 | N/A | -28 | -19 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HOWL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HOWL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HOWL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HOWL's revenue (31% per year) is forecast to grow faster than the US market (8.5% per year).
High Growth Revenue: HOWL's revenue (31% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HOWL's Return on Equity is forecast to be high in 3 years time